Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer
With its high mortality, pancreatic cancer is the fourth highest cause of cancer deaths in developed countries. It is projected to be the second leading reason of cancer-related deaths in the next decade [1,2]. This poor prognosis is affected, among others, by a late diagnosis due to a lack of specific symptoms. The only curative treatment option is surgical resection [3]. Patients with locally advanced pancreatic cancer (LAPC) receive neoadjuvant chemotherapy or radiochemotherapy intending to achieve a secondary resection.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Jana Kern, Daniela Schilling, Christian Schneeweis, Roland M. Schmid, G ünter Schneider, Stephanie E. Combs, Sophie Dobiasch Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Radiology